Loading...
XNAS
CLDX
Market cap1.96bUSD
Dec 05, Last price  
29.45USD
1D
-0.51%
1Q
28.77%
Jan 2017
731.92%
Name

Celldex Therapeutics Inc

Chart & Performance

D1W1MN
XNAS:CLDX chart
P/E
—
P/S
278.76
EPS
—
Div Yield, %
—
Shrs. gr., 5y
34.73%
Rev. gr., 5y
14.46%
Revenues
7m
+1.99%
3,088,3414,931,0975,102,9307,455,50715,180,00046,793,0009,265,00011,202,0004,111,0003,586,0005,480,0006,786,00012,743,0009,538,0003,573,0007,418,0004,651,0002,357,0006,883,0007,020,000
Net income
-158m
L+11.62%
-18,096,569-20,373,932-21,638,761-47,500,571-36,525,000-2,533,000-44,799,000-59,123,000-81,550,000-118,080,000-127,197,000-128,530,000-93,031,000-151,184,000-50,372,000-59,780,000-70,511,000-122,783,000-141,429,000-157,863,000
CFO
-158m
L+47.06%
-6,016,63027,000,319-19,302,98618,280,766-29,869,000-30,372,000-35,658,000-49,782,000-67,669,000-101,537,000-98,887,000-113,036,000-99,931,000-75,235,000-46,415,000-40,404,000-60,909,000-103,732,000-107,291,000-157,778,000

Notes

No notes on this company yet
Write a private note on this company, for your eyes only
Add note

Profile

Celldex Therapeutics, Inc., a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory diseases and various forms of cancer. The company's clinical development programs CDX-0159, a Phase I monoclonal antibody that binds the receptor tyrosine kinase KIT and inhibits its activity; CDX-1140, a human agonist monoclonal antibody targeted to CD40, a key activator of immune response, which is found on dendritic cells, macrophages, and B cells, as well as is expressed on various cancer cells; and CDX-527, a bispecific antibody, which uses the company's proprietary active anti-PD-L1 and CD27 human antibodies to couple CD27 costimulation with blockade of the PD-L1/PD-1 pathway to help prime and activate anti-tumor T cell responses through CD27 costimulation. The company has research collaboration and license agreements with University of Southampton to develop human antibodies towards CD27; Amgen Inc. with exclusive rights to CDX-301 and CD40 ligand; and Yale University. Celldex Therapeutics, Inc. was incorporated in 1983 and is headquartered in Hampton, New Jersey.
URL
https://celldex.com/
IPO date
May 15, 1986
Employees
148
Domiciled in
US
Incorporated in
US

Valuation

Title
USD in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT